MedTrace Logo

Post Approval Study of the Eversense® Continuous Glucose Monitoring

NCT03908125 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2025-06-12

Study results available
· View outcomes & findings →

Summary

A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the Eversense® CGM System

Conditions

Interventions

DEVICE

Eversense® CGM System

Continuous Glucose monitoring device

Sponsors & Collaborators

  • Senseonics, Inc.

    lead INDUSTRY

Principal Investigators

  • Kathleen Davis · Senseonics, Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-19
Primary Completion
2024-02-01
Completion
2024-02-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03908125 on ClinicalTrials.gov